CDP

CDP-840 (GR259653X) is a potent, selective, and orally active phosphodiesterase IV (PDE IV) inhibitor that specifically inhibits antigen-induced early and late phase bronchoconstriction in conscious squirrel monkeys [1].

16:0 CDP DG ammonium is a type of lipid nucleotide.

Cytidine 5'-diphosphate trisodium salt (CDP) catalyzes the production of Cytidine triphosphate (CTP) for DNA and RNA synthesis by transferring a phosphoryl group from ATP to cytidine monophosphate (CMP) through the action of uridine monophosphate kinase (UMPK).

Cytidine 5′-diphosphat (5'-CDP) is synthesized from cytidine monophosphate (CMP) or uridine monophosphate (UMP) by the transfer of phosphoryl group, catalyzed by the enzyme uridylate kinase (UMPK).

Citicoline (CDP-Choline) is an intermediate in the synthesis of phosphatidylcholine, a component of cell membranes. Citicoline exerts neuroprotective effects.

Citicoline sodium (CDP-choline) is an endogenous intermediate in the synthesis of phosphatidylcholine. It also serves as a choline donor in the biosynthesis of the neurotransmitter acetylcholine. Citicoline sodium demonstrates protective effects in cerebral ischemia, traumatic brain injury, and memory disorders. Exogenous administration of citicoline to rodents (500 mg/kg i.p. immediately after ischemia and at 3-h reperfusion) has been shown to stimulate the synthesis of phosphatidylcholine, sphingomyelin, and cardiolipin and to attenuate the release of arachidonic acid and the accumulation of ceramide.

Cytidine 5'-diphosphate disodium (CDP sodium salt) produces CTP to support DNA and RNA biosynthesis and ribonucleotide reductase to produce dCMP.

Zaurategrast ethyl ester sulfate is a α4β1/α4β7 integrin antagonist, and used for the treatment of inflammatory and autoimmune disorders.

Zaurategrast ethyl ester is the ethyl ester prodrug of CT7758 and is an α4β1/α4β7 integrin antagonist. It is used for the treatment of inflammatory and autoimmune disorders.

Senlizumab is a human-derived antibody expressed in CHO cells, targeting TNFSF2/TNFa. It features a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.9 kDa. For its isotype control, refer to HumanIgG4kappa, Isotype Control.

1,2-Dioleoyl-sn-glycero-3-(cytidine diphosphate) ammonium (18:1 CDP DG) is a derivative of diacylglycerol.

CDP-β-S (Cytidine-5'-O-(2-thiodiphosphate)) trisodium salt is a non-hydrolyzable analog of CDP (Cytidine Diphosphate) with antioxidant and free radical scavenging properties.

CDP-Star is a luminescent substrate for 1,2-dioxetane and a substrate for alkaline phosphatase.CDP-Star can be used for in vivo imaging by detecting mRNA on Northern blot.

CDP-484 is an inhibitory antibody that can be used in life science related research.

CDP-Ribitol serves as the donor substrate for the RboP transferases fukutin and FKRP.

2'-F-CDP is a nucleotide analog that can be utilized in the synthesis of oligonucleotides.

Cytidine-5'-O-(2-thiodiphosphate) (CDP-β-S), a non-hydrolyzable derivative of CDP exhibiting antioxidant activity, effectively scavenges free radicals as evidenced by its performance in the Trolox equivalent absorbance capacity (TEAC) assay at concentrations between 5 and 20 µM.

CpCDPK1/TgCDPK1-IN-3 is a dual inhibitor of CpCDPK1 and TgCDPK1 with an IC50 of 0.003 µM for CpCDPK1 and 0.0036 µM for TgCDPK1. CpCDPK1/TgCDPK1-IN-3 can be used to study infections associated with diseases such as Toxoplasma, Cryptosporidium and Cryptosporidium.

CpCDPK1/TgCDPK1-IN-2 is a dual inhibitor of CpCDPK1 and TgCDPK1 with IC50 values of 12 and 5 nM for CpCDPK1 and TgCDPK1, respectively.CpCDPK1/TgCDPK1-IN-2 can be used in the study of diseases associated with infection of toxoplasmas such as Toxoplasma gondii, Cryptosporidium parvum and C. hominus. CpCDPK1/TgCDPK1-IN-2 can be used to study diseases associated with infections of toxoplasma gondii (T. gondii), Cryptosporidium parvum (C. parvum), and Cryptosporidium hominus (C. hominus).

CpCDPK1/TgCDPK1-IN-1 is a potent dual inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections and cryptosporidiosis.

(+)-CBI-CDPI1, an enhanced functional analog of CC-1065, is a DNA alkylating agent and an antibody-drug conjugate (ADCs) toxin.

(+)-CBI-CDPI2 is an enhanced functional analog of CC-1065.

ACDPP is a specific antagonist of metabotropic glutamate receptor 5 (mGluR5) that partially blocks the DHPG-induced increase of fragile X mental retardation protein (FMRP), ACDPP is used as a pharmacological tool in neuroscience research to study group I mGluR signaling, synaptic plasticity, and molecular mechanisms underlying fragile X syndrome.

CDPPB is a modulator of mGluR5 positive allosteric(with an EC50 of 27 nM in Chinese hamster ovary cells expressing human mGluR5).